ad

Banka BioLoo Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

14 Apr 202611:13 am

Banka BioLoo Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Banka BioLoo (BANKABIOLOO) Q4 FY26 results are scheduled for May 15, 2026, when the company’s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 88 as of April 2026 — down -41% from its 52-week high of Rs 155 — the stock has been under pressure alongside its peers in the Sanitation / ESG Infrastructure sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.

Banka BioLoo’s Q4 FY26 earnings will be watched for signals on the company’s +20% revenue YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.

Get free investment predictions on Univest.

Banka BioLoo Q4 Results 2026 Date

The Banka BioLoo Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.

Here is a broader view of the Q4 FY26 results calendar for reference:

CompanyResults DateKey Metric
TCSApril 9, 2026 (Declared)FY27 revenue guidance, deal TCV
InfosysApril 23, 2026CC growth guidance for FY27
Bharat Electronics (BEL)May 8, 2026Order book execution, EBITDA margin
Bharat ForgeMay 10, 2026Global CV + defence execution
Banka BioLooMay 15, 2026See estimates below

Why Q4 FY26 Matters

Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.

For Banka BioLoo specifically, Q4 FY26 captures the peak season dynamics of the Sanitation / ESG Infrastructure sector. Management’s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.

Banka BioLoo Q4 FY26 Earnings Estimates

Banka BioLoo Q4 FY26 analyst consensus estimates — Revenue, PAT, Margin

Access premium research on Univest.

Based on publicly available analyst consensus, here are the Q4 FY26 estimates for Banka BioLoo:

MetricQ4 FY26 EstimateQ3 FY26 ActualTrend
RevenueRs 42 CrRs 35 CrQoQ expected improvement
Net Profit (PAT)Rs 4 CrRs 3 CrNormalisation expected
MarginEBITDA 10%Q3 FY26 marginQoQ trend
Volume / Growth Driver+20% revenue YoYPrior quarterYoY
Dividend (Expected)Rs 0 (no dividend)FY26 interim dividendsFinal dividend

Screen Banka BioLoo live fundamentals on the Univest Screener.

Download the Univest iOS App or Univest Android App for real-time Q4 result alerts and analyst updates.

5 Key Factors Driving Banka BioLoo Q4 FY26 Performance

1. Government Sanitation Contracts

Banka BioLoo installs bio-toilet systems for Indian Railways, military establishments, and government bodies. Swachh Bharat Mission Phase 2 funding and Indian Railways’ modernisation programme are the primary revenue drivers.

2. Bio-Digester Technology

The company’s proprietary bio-digester technology for portable and permanent toilets positions it in the growing sanitation infrastructure market. Technology differentiation creates competitive moat in specific segments.

3. Rural Sanitation Drive

Rural India’s sanitation infrastructure continues to receive government investment. Banka BioLoo’s low-cost bio-toilet solutions for rural community use are a growing segment.

4. Defence and Military Installations

Defence establishment sanitation contracts provide a stable, high-quality revenue stream with government payment guarantees.

5. ESG Investor Interest

Companies addressing India’s sanitation gap attract ESG-focused investor attention, which can create valuation premiums relative to financial metrics.

5 Risks to Watch in Banka BioLoo Q4 FY26

Risk 1: Government Payment Timelines

Government contract payments can be delayed, creating working capital stress.

Risk 2: Small Scale

At Rs 185 crore market cap, this is a micro-cap company with governance and liquidity risks.

Risk 3: Contract Concentration

Revenue concentrated in few large government contracts creates quarterly lumpiness.

Risk 4: Technology Competition

Larger sanitation infrastructure companies can develop or license similar technologies.

Risk 5: Execution Complexity

Large-scale toilet installation projects require managing supply chains, installation teams, and quality across diverse geographic locations.

Banka BioLoo Share Price and Analyst Ratings

Banka BioLoo share price and analyst ratings — Q4 FY26 preview
ParameterValue
CMP (April 2026)Rs 88
52-Week HighRs 155
52-Week LowRs 72
1-Year Return-41%
Market CapitalisationRs 185 Cr
SectorSanitation / ESG Infrastructure
NSE TickerBANKABIOLOO

Analyst ratings and target prices based on publicly available brokerage research:

BrokerageRatingTarget PriceInvestment Thesis
Hem SecuritiesBUYRs 115Swachh Bharat spending continues
Marwadi SharesNEUTRALRs 90Execution risk at scale

Conclusion

Banka BioLoo Q4 FY26 will reflect government sanitation contract execution. Revenue above Rs 42 crore with positive EBITDA would be a beat. The Indian Railways and Swachh Bharat Mission pipeline provides multi-year revenue visibility.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Banka BioLoo Q4 results 2026 date?

Banka BioLoo Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.

Q: What is Banka BioLoo Q4 FY26 revenue estimate?

Analyst consensus estimate for Banka BioLoo Q4 FY26 revenue is Rs 42 Cr. Q3 FY26 actual revenue was Rs 35 Cr. Actual Q4 results may vary based on operating conditions.

Q: What is Banka BioLoo Q4 FY26 PAT estimate?

Analyst consensus estimate for Banka BioLoo Q4 FY26 net profit (PAT) is Rs 4 Cr. Q3 FY26 actual PAT was Rs 3 Cr. Estimates are indicative and not guaranteed.

Q: Will Banka BioLoo declare a dividend in Q4 FY26?

Banka BioLoo is expected to declare Rs 0 (no dividend) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.

Q: What is Banka BioLoo current share price?

Banka BioLoo is trading at Rs 88 as of April 2026, with a 52-week range of Rs 72 to Rs 155. The 1-year return is -41%.

Q: What were Banka BioLoo Q3 FY26 results?

In Q3 FY26, Banka BioLoo reported revenue of Rs 35 Cr and net profit (PAT) of Rs 3 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 (see the Banka BioLoo earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.

Q: Is Banka BioLoo a good investment ahead of Q4 results?

This article does not constitute investment advice. Banka BioLoo trades at Rs 88 with a 52-week range of Rs 72 to Rs 155. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.

Recent Article

Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

ad

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited

Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003

Write to us : support@univest.in, compliance@univest.in

Verify on SEBI registry →

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
Google for Startups Accelerator 2024
Trusted by 70 lakh+ Indians
Awarded No. 1 by Economic times